Abstract:Background:Depression is a serious psychiatric disorder that creates a major public health burden of disease and disability. It is quite widespread;approximately 16% of individuals in the United States have suffered from clinical depression during their lifetime. While antidepressants have been available for several decades,most of them are not totally effective. New approaches to clinically treating depression are thus needed,and the molecular and cellular mechanisms underlying the pathophysiology of depression could provide a new therapeutic target. Cyclin-dependent kinase 5 (Cdk5),is a proline-directed serine/threonine kinase that is highly active in the brain and is important for the development of the central nervous system. Cdk5 has been implicated in synaptic plasticity,which underlies learning and memory,as well as neuropsychiatric pathologies like depression and bipolar disorder. Recently,it also has been reported that inhibition of Cdk5 activity in the hippocampus facilitates extinction of learned contextual fear memory,suggesting that Cdk5 could be a potential target for treatment of emotional disorders. However,hippocampal Cdk5’s potential role in the development of depressive diseases has not been examined.Objectives:To investigate the possible roles that Cdk5/p35 might play in the development of depressive-like symptoms,using the chronic mild stress rat model. Methods:Two hundred and ninety-two male Sprague-Dawley rats (weighing 200-220 g at the start of the study) were individually housed under a constant temperature (23±s 2 degrees Celsius) and maintained on a 12 h light/dark cycle with free access to food and water. In order to examine the effects of Cdk5/p35 activity in hippocampus on depressive-like behavior,rats were subjected to the chronic mild stress procedure for 3 weeks. Subsequently,the depressive-like behaviors including sucrose preference,bodyweight increase and locomotor activity were examined;Cdk5 kinase activity was measured by an in vitro phosphorylation assay,and membrane and cytosolic p35 levels were detected by Western blot analysis. In order to investigate whether Cdk5 is functionally related to the depressive-like symptoms elicited by the CMS procedure,Buty,a Cdk5 inhibitor,was infused into DG,CA1 and CA3 subfield,respectively. Over the next 3 weeks,they received injections in DG,CA1 or CA3 on days 1,7,14 and 21,as detailed in a previous study. The control groups received intra-DG,CA1 or CA3 injection of saline containing 0.2% DMSO or different doses of Buty (25,50 and 100 ng). The chronic mild stress groups were given intra-DG,CA1 or CA3 injections of saline containing 0.2% DMSO and different doses of Buty (25,50 and 100 ng) during the 3 weeks of chronic mild stress. Each intracranial injection was administrated between 8.00-10.00 am,1 h prior to stress exposure to the stressor. The day after the last stress exposure,the sucrose preference test was performed and then the animals were decapitated. Subsequently,bilateral tissue punches from CA1,CA3 and DG (16 gauge) were obtained. Proteins were extracted for kinase activity measurement and Western blot assay. The subsequent experiment was designed to determine the role p35 translocation plays in the actions of antidepressants. Four groups of rats (n=8 per group) were used to examine effects of the antidepressant venlafaxine on DG p35 translocation using a 2×2 design with the between-subject factors of Group (Control or CMS) and Treatment (vehicle or venlafaxine). The other four groups of rats (n=8 per group) were used to examine the effects of the antidepressant mirtazapine on DG p35 translocation using a 2×2 design,with the between-subject factors Group (Control or CMS) and Treatment (vehicle or mirtazapine). Intraperitoneal drug or vehicle injections were performed for 21 consecutive days in both the control and CMS groups. The day after the last stress exposure,the sucrose preference test was performed and the animals were decapitated. Subsequently,bilateral DG tissue punches (16 gauge) were obtained. The cytoplasmic and membrane protein levels were measured by Western blot assay. Results:CMS increased hippocampal Cdk5 activity,which was accompanied by an upregulation of membrane p35,a Cdk5 activator,and a reduction of cytosolic p35 in the dentate gyrus (DG). Microinjection of a Cdk5 inhibitor,butyrolactone,in DG,but not in CA1 or CA3,reversed the depressive-like behaviors induced by CMS. A negative linear correlation was found between sucrose preference,bodyweight increase and the membrane p35 level in DG. Chronic treatment with antidepressants venlafaxine and mirtazapine,but not the antipsychotic aripiprazole,prevented the aberrant translocation of p35 induced by CMS in DG. Conclusion:Our results revealed that the development of depressive-like behavior was associated with increased Cdk5 activity through p35 translocation from the cytosol to the membrane in DG. These findings suggest that hippocampal Cdk5/p35 complex mediated the depressive-like behavior induced by CMS;thus,Cdk5 could be a novel target for therapeutic treatment of major depression.

Valproic Acid-Induced Anxiety and Depression Behaviors are Ameliorated in p39 Cdk5 Activator-Deficient Mice

Valproate Reverses Mania-Like Behavior of Clock Delta19 Mouse and Alters Monoamine Neurotransmitters Metabolism in the Hippocampus.

Valproic Acid Influences MTNR1A Intracellular Trafficking and Signaling in a β-Arrestin 2-Dependent Manner

Valproate Administration to Mice Increases Histone Acetylation and 5-Lipoxygenase Content in the Hippocampus.

Valproate Reverses Mania-Like Behavior of Clockdelta19 Mouse and Alters Monoamine Neurotransmitters Metabolism in the Hippocampus

Microinjection of valproic acid into the ventrolateral orbital cortex exerts an antidepressant-like effect in the rat forced swim test.

Class I Histone Deacetylase Inhibitor Valproic Acid Reverses Cognitive Deficits in a Mouse Model of Septic Encephalopathy

Defects of Parvalbumin-Positive Interneurons in the Ventral Dentate Gyrus Region Are Implicated Depression-Like Behavior in Mice.

CYCLIN-DEPENDENT KINASE 5 IN THE DENTATE GYRUS MEDIATES DEPRESSIVE-LIKE BEHAVIOR IN RATS

Prenatal exposure to valproic acid reduces synaptic δ-catenin levels and disrupts ultrasonic vocalization in neonates

Role of BDNF-TrkB Pathway in the Protective Effects of Valproic Acid against Septic Encephalopathy in Mice

Valproic acid activates ERK-1/2 signaling pathway in the rat hippocampus and frontal cortex

Valproic Acid Alleviates Memory Deficits and Attenuates Amyloid-β Deposition in Transgenic Mouse Model of Alzheimer’s Disease

Valproic acid effects in the hippocampus and prefrontal cortex in an animal model of post-traumatic stress disorder

Increased Cdk5/P35 Activity In The Dentate Gyrus Mediates Depressive-Like Behaviour In Rats

Effect of valproic acid on autonomous behaviors and cerebral morphology and structure in APP/PS1 double transgenic mice

Valproate robustly enhances AP-1 mediated gene expression.

Deletion of the Mitochondrial Matrix Protein CyclophilinD Prevents Parvalbumin Interneuron Dysfunctionand Cognitive Deficits in a Mouse Model of NMDA Hypofunction

C-Jun Amino-Terminal Kinase is Involved in Valproic Acid-Mediated Neuronal Differentiation of Mouse Embryonic NSCs and Neurite Outgrowth of NSC-Derived Neurons

The Effects of Antiepileptic Drug Valproic Acid on Apoptosis of Hippocampal Neurons in Epileptic Rats.

The mood stabilizer valproate activates human FGF1 gene promoter through inhibiting HDAC and GSK-3 activities